A pharmaceutical composition for use in the treatment of various skin wounds, wherein an important component of pharmaceutical composition comprises glycerol, 1,2-propanediol, water-soluble laurocapram or decyl methyl sulfoxide, and water in a specific ratio, wherein the glycerol is present in the composition in an amount of 80% to 90% by volume, wherein the pharmaceutical composition is characterized by at least one of the following: 1) the 1,2-propanediol is present in the composition in an amount of 6-15% by volume; 2) the water-soluble laurocapram is present in the composition in an amount of 0.2% to 2% by volume, preferably in an amount of 0.6% to 1% by volume, and more preferably in an amount of 0.2% to 0.5% by volume; 3) the decyl methyl sulfoxide is present in the composition in an amount of 1% to 4% by volume, preferably in an amount of 1% to 3% by volume, and more preferably in an amount of 1% to 1.5% by volume; 4) the water is present in the composition in an amount of 3% to 8% by volume, preferably in an amount of 3% to 5% by volume, and more preferably in an amount of 3% to 4% by volume, wherein the pharmaceutical composition further comprises at least one of Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, and Paeoniae Radix Rubra; and the pharmaceutically effective components in at least one of the Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, and Paeoniae Radix Rubra are extracted by hydrated glycerol under high temperature and high pressure; and wherein the pharmaceutical composition further comprises at least one of Olibanum, Myrrha, Draconis Sanguis, and Catechu; and the pharmaceutically effective components in at least one of Olibanum, Myrrha, Draconis Sanguis, and Catechu are extracted by immersion method with 1,2-propanediol. 1) the 1,2-propanediol is present in the composition in an amount of 6-15% by volume; 2) the water-soluble laurocapram is present in the composition in an amount of 0.2% to 2% by volume, preferably in an amount of 0.6% to 1% by volume, and more preferably in an amount of 0.2% to 0.5% by volume; 3) the decyl methyl sulfoxide is present in the composition in an amount of 1% to 4% by volume, preferably in an amount of 1% to 3% by volume, and more preferably in an amount of 1% to 1.5% by volume; 4) the water is present in the composition in an amount of 3% to 8% by volume, preferably in an amount of 3% to 5% by volume, and more preferably in an amount of 3% to 4% by volume, wherein the pharmaceutical composition further comprises at least one of Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, and Paeoniae Radix Rubra; and the pharmaceutically effective components in at least one of the Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, and Paeoniae Radix Rubra are extracted by hydrated glycerol under high temperature and high pressure; and wherein the pharmaceutical composition further comprises at least one of Olibanum, Myrrha, Draconis Sanguis, and Catechu; and the pharmaceutically effective components in at least one of Olibanum, Myrrha, Draconis Sanguis, and Catechu are extracted by immersion method with 1,2-propanediol. wherein the pharmaceutical composition further comprises at least one of Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, and Paeoniae Radix Rubra; and the pharmaceutically effective components in at least one of the Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, and Paeoniae Radix Rubra are extracted by hydrated glycerol under high temperature and high pressure; and wherein the pharmaceutical composition further comprises at least one of Olibanum, Myrrha, Draconis Sanguis, and Catechu; and the pharmaceutically effective components in at least one of Olibanum, Myrrha, Draconis Sanguis, and Catechu are extracted by immersion method with 1,2-propanediol. <EOS>